InflaRx follow-on offering
The shares are listed on the Nasdaq Global Market
Davis Polk advised the representative of the underwriters in connection with a public offering by InflaRx N.V. of an aggregate of 9,411,765 of its ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the symbol “IFRX.”
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a / C5aR technologies to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate David Li. Partner Corey M. Goodman and associates Tyler Scheiner and Michelle Zhao provided tax advice. Partner David R. Bauer and associate Shreya R. Kundur provided intellectual property advice. All members of the Davis Polk team are based in the New York office.